A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

452 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This registry collects observational data about how mid-length AngioJet catheters (ie XPEEDIOR and DVX models) are used in routine clinical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Efficacy and Safety of Midline Venous Catheters

NCT05835531

Midline Catheter

UNKNOWN

Description of Septic Thrombophlebitis on Central Venous Catheter and Midline

NCT05743738

Septic Thrombophlebitis

RECRUITING NA

Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement

NCT01988766

Thrombosis

COMPLETED

Evaluation of the Contribution of the Ultrasound Tracking and the Positioning of the Distal End During the Implantation of Implantable Chamber or Long-lasting Venous Catheter

NCT03133962

Echocardiography Implantable Chamber

WITHDRAWN NA

Peripherally Inserted Internal Jugular Catheters: an Observational Study

NCT03523533

Intravenous Drug Usage

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PEARL Registry collects real world data about mid-length AngioJet catheters to:

* Characterize usage patterns, treatment approaches, and targeted vessels
* Document treatment strategies, including specific techniques and concomitant therapies
* Collect outcome data during initial hospitalization and at a 3-month follow-up phone call or visit
* Evaluate the frequency of specific clinical events in relation to risk factors, diagnosis, and treatments provided
* Identify treatment strategies that may optimize procedural and clinical outcomes, to facilitate development of treatment guidelines
* Offer sites a valuable resource for tracking usage and performance of the AngioJet System at their institution

Information collected by the PEARL Registry is intended for educational and clinical research purposes only.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Vascular Diseases Thrombosis Venous Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Limb Ischemia

Patients presenting with limb ischemia for treatment

No interventions assigned to this group

Deep Vein Thrombosis

Patients presenting with deep vein thrombosis for treatment

No interventions assigned to this group

Hemodialysis Access

Patients presenting with thrombosed hemodialysis access for treatment

No interventions assigned to this group

Other Thrombotic Conditions

Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has been treated with a mid-length AngioJet catheter(defined as 90-120 cm in length)
* Patient has provided appropriate authorization per institutional policy and procedure.